Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan

This article was originally published in The Tan Sheet

Executive Summary

Nonsedating antihistamines classified as prescription drugs would be more appropriately sold as OTCs, Blue Cross of California Pharmacy VP Rob Seidman maintains in Jan. 12 letters sent to marketers of the drugs.
Advertisement

Related Content

Rx Label Use Permissible Even If FDA Finds Drug Is Safe OTC – Attorney
Nicotrol Inhaler Behind-The-Counter Status Sought By Pharmacist Group
FDA-Initiated OTC Switches Could Be Based On Foreign Data – McClellan
FDA Cautious On Forced Rx-To-OTC Switches
Rx-To-OTC Switch Guidance May Be Issued By FDA
FDA Announces “Proactive” Approach To Rx-To-OTC Switches
WellPoint Clarinex Switch Petition Assertions Are “Troubling” – NCL
Allegra, Zyrtec Will Not Follow Claritin OTC In Near Future, Execs State
Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray
Pfizer Consumer Health Is “Logical Extension” Of Rx – CEO McKinnell

Topics

Advertisement
UsernamePublicRestriction

Register

PS089334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel